Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHA@ZIF-8
- Development stage
- Preclinical
- Lead developer
- Hubei Medical College
01
Overview
DHA@ZIF-8: sourced facts only. name: "Further investigations presented zinc ions and DHA released from the DHA@ZIF-8, which located in lysosome, acted as a direct inhibitor of OCT4." [PMID:42020944]; target: "Further investigations presented zinc ions and DHA released from the DHA@ZIF-8, which located in lysosome, acted as a direct inhibitor of OCT4." [PMID:42020944]; developer: "Department of Pulmonary and Critical Care Medicine, Shiyan Key Laboratory of Major Chronic Respiratory Disease, Taihe Hospital, Hubei University of Medicine, Renmin Road No. 30, Shiyan, Hubei 442000, China." [PMID:42020944]; stage: "The prolonged survival of MPE mice treated with DHA@ZIF-8 was observed with reduced volume of MPE compared with the control group, as evidenced by micro-CT and ultrasonic images." [PMID:42020944]
02
Targets
POU5F1 (Octamer-binding transcription factor 4)
Beyond the preview
Go deeper on DHA@ZIF-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHA@ZIF-8.